Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens. - Wikidata - awgldk - TriplyDB

Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.

Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.

http://www.wikidata.org/entity/Q37263328

about

Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade.

P2860

Q33698075-A30CDA5A-0755-4ACF-B719-B28BEDB05EE1 Q38209673-9D149AA3-08B6-44C6-AF34-ED81922182D7

P2860

Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.

http://www.wikidata.org/entity/Q37263328

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Bioluminescence-based neuramin ...... ibility in clinical specimens.

@en

Bioluminescence-based neuramin ...... ibility in clinical specimens.

@nl

type

label

Bioluminescence-based neuramin ...... ibility in clinical specimens.

@en

Bioluminescence-based neuramin ...... ibility in clinical specimens.

@nl

prefLabel

Bioluminescence-based neuramin ...... ibility in clinical specimens.

@en

Bioluminescence-based neuramin ...... ibility in clinical specimens.

@nl

P1433

Q37263328-8D477E3C-2E6B-4DF1-A706-C5E5AD2FDCF0

P1476

Q37263328-1FAF14C9-25DD-42D8-BEF7-7D55625AE525

P2093

Q37263328-0444F886-5715-4BB4-8D6B-9FDFD77CFA45

Q37263328-44A98486-BE26-47DF-8B35-5F9278E57879

Q37263328-494AA5A7-4168-4BD2-979C-4117DDF84671

Q37263328-7951E86D-1E53-4D52-B03A-F7F5F2240270

Q37263328-8445F2F4-ABBF-4881-B582-F5A68E7E8F6E

Q37263328-CAC91C5A-49F9-4577-B948-E99BBD027A54

Q37263328-CC70B597-1F2E-4F40-8FF3-3B0DA85F1F47

Q37263328-D2236A50-9886-4AA3-BAA4-367FF3D51254

P2860

Q37263328-03BF7C24-EBB6-4FDD-9440-9530BE6FD000

Q37263328-10B24768-462E-4411-BC70-8406D26BF5A0

Q37263328-112DFE39-61FD-48C1-88C5-AA58E28EA464

Q37263328-1A419491-D87C-4C30-BA2B-5E61326BD38F

Q37263328-1FA9EDEF-D80F-4FA2-A8C4-B8EB5B84E525

Q37263328-21F9F976-28D3-480A-BA23-138F1B267FF8

Q37263328-2CDBBA2D-F68E-4573-8871-AD1B6A8FE8AA

Q37263328-3B90222A-684A-4DEB-BAE3-78A51BFE2012

Q37263328-3EB04BDF-D068-40CD-81A3-AB47D8CA11E9

Q37263328-4D109D09-8C83-44DA-A89E-B44813FFAE9D

P304

Q37263328-D97088BE-466D-423E-8BA6-FF8198E1E21E

P31

Q37263328-0849B49D-D83E-459A-BFF4-14FE5189D3D0

P356

Q37263328-40945FF1-1255-4FDA-9BCB-8F670A6D842D

P407

Q37263328-29583F7F-FD46-420C-9009-562784EE0645

P433

Q37263328-2FAA7F38-B443-4FBF-8714-A55445C4C9E7

P478

Q37263328-E1F6ACFF-D54F-4C77-BCC4-8E41B797CD7E

P577

Q37263328-FA403798-8B76-4127-809E-9FDB2AB468F3

P5875

Q37263328-0428B65E-664F-4305-9C31-A5CEF77621E5

P698

Q37263328-0024656A-EA2C-4016-9DB7-E5E97019C724

P921

Q37263328-0B896E5B-9555-4B52-AA5E-E5AA8EFD73EF

P932

Q37263328-EB4536B7-83F8-414B-B8DF-A02ED15CA9D4

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Bioluminescence-based neuramin ...... ibility in clinical specimens.

@en

P2093

Henju Marjuki

http://www.w3.org/2001/XMLSchema#string

Katrina Sleeman

http://www.w3.org/2001/XMLSchema#string

Larisa V Gubareva

http://www.w3.org/2001/XMLSchema#string

Lizheng Guo

http://www.w3.org/2001/XMLSchema#string

Margaret Okomo-Adhiambo

http://www.w3.org/2001/XMLSchema#string

Tiffany G Sheu

http://www.w3.org/2001/XMLSchema#string

Vasiliy P Mishin

http://www.w3.org/2001/XMLSchema#string

Xiyan Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.

Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing.

Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.

H1N1pdm influenza infection in hospitalized cancer patients: clinical evolution and viral analysis.

Design and performance of the CDC real-time reverse transcriptase PCR swine flu panel for detection of 2009 A (H1N1) pandemic influenza virus

Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.

Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States.

Peramivir for the treatment of influenza.

The chemiluminescent neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.

The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.

P304

5209-5215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01086-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255689076

http://www.w3.org/2001/XMLSchema#string

P698

23917311

http://www.w3.org/2001/XMLSchema#string

P921

bioluminescence

P932

3811246

http://www.w3.org/2001/XMLSchema#string